HC Wainwright Has Negative Estimate for OCUL Q3 Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – HC Wainwright dropped their Q3 2026 earnings estimates for Ocular Therapeutix in a research note issued to investors on Tuesday, August 4th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will post earnings of ($0.37) per share for the quarter, down from their prior estimate of ($0.36). HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Ocular Therapeutix’s FY2026 earnings at ($1.49) EPS, Q3 2027 earnings at ($0.38) EPS, Q4 2027 earnings at ($0.38) EPS and FY2027 earnings at ($1.54) EPS.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $13.47 million for the quarter, compared to analyst estimates of $13.20 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the prior year, the business earned ($0.39) earnings per share.

OCUL has been the topic of a number of other research reports. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Ocular Therapeutix in a report on Tuesday, May 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Friday, July 17th. Chardan Capital restated a “buy” rating and issued a $23.00 price objective on shares of Ocular Therapeutix in a research report on Tuesday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research note on Wednesday, May 6th. Finally, Zacks Research cut Ocular Therapeutix from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Ocular Therapeutix presently has an average rating of “Moderate Buy” and an average target price of $25.75.

Ocular Therapeutix Trading Down 1.0%

Shares of Ocular Therapeutix stock opened at $8.50 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 14.73. Ocular Therapeutix has a 1 year low of $6.23 and a 1 year high of $16.44. The company has a market capitalization of $1.87 billion, a P/E ratio of -5.99 and a beta of 0.93. The business has a 50 day moving average price of $9.16 and a 200 day moving average price of $9.13.

Institutional Trading of Ocular Therapeutix

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC raised its position in shares of Ocular Therapeutix by 124.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,242 shares during the period. Rockefeller Capital Management L.P. purchased a new stake in Ocular Therapeutix during the fourth quarter valued at about $31,000. Hilton Head Capital Partners LLC grew its position in Ocular Therapeutix by 30.4% during the first quarter. Hilton Head Capital Partners LLC now owns 4,520 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,053 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in Ocular Therapeutix during the fourth quarter worth about $61,000. Finally, KBC Group NV acquired a new stake in Ocular Therapeutix during the fourth quarter worth about $78,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,156 shares of the stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares of the company’s stock, valued at $21,296,794. This trade represents a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 28,999 shares of company stock worth $237,792 over the last quarter. Company insiders own 3.10% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.